Informatics
Supporting bioprocess
While the specific techniques used in the develop- ment of small and large molecule drugs are very different, the need to capture data and the associ- ated analysis, interpretation and reports is the same. The increasing use of laboratory automation around purification and analytical techniques is resulting in a data explosion – similar to that expe- rienced in the small molecule world over the last few decades. Labs are generating much more data than previously, and with the advent of new tech- niques such as next generation sequencing and pro- tein mass spectrometry, the rate of growth is also unprecedented. This evolution and ‘data deluge’ only heightens the need for data management solu- tions to help scientists protect and leverage corpo- rate knowledge. Fundamentally, bioprocess organisations devel- op and implement cell, production and purification platforms. The data and knowledge cascade required to develop these platforms is dependent on many different domains being linked together and each domain having a specific view of that
data: precisely the same high level requirement as small molecule development. The precise tech- niques, data types and science in biologics drug development such as molecular biology, cell line manipulation, fermentation, purification and for- mulations are all quite different to the small mole- cule domains. However, the collaboration, devel- opment and validation practices, regulatory over- sight and the existence of data providers and con- sumers are identical. This means therefore that the foundation to support these practices can be the same – scientific information being preserved in an Enterprise ELN as part of the company’s knowl- edge base4.
There is a further implication for pharmaceutical companies developing both small and large mole- cules. For an Enterprise ELN to be capable of sup- porting both macro domains, consistent data man- agement, analysis, reporting and validation approaches are required, which can simplify and streamline interactions with regulatory bodies, potentially reducing the total cost of ownership and maintenance of the system.
An integrated, sophisticated data management solution
BD Pathway™ High-Content Imaging Systems now incorporate the key features of BD AttoVision™ 1.7 software. BD AttoVision 1.7 software data management works seamlessly with an SQL-based server so that researchers obtain and maintain increased knowledge from their experiments. With BD AttoVision 1.7 software, users can store and synchronize data in a central repository. Centralized storage simplifies data management, allows creation of custom classification hierarchies, and speeds the execution and saving of custom queries based on metadata.
BD, BD Logo and all other trademarks are the property of Becton, Dickinson and Company. © 2010 BD A719-01
Bioimaging Systems Tel.: (32) 2 400 98 95 Fax: (32) 2 401 70 94
bdbiosciences.com
Drug Discovery World Summer 2010
45
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92